Q1 Earnings Forecast for AVDL Issued By Lifesci Capital

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Stock analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a report issued on Monday, March 3rd. Lifesci Capital analyst M. Belghiti forecasts that the company will earn ($0.04) per share for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals’ Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.15 EPS.

Several other research firms also recently commented on AVDL. UBS Group cut their target price on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Piper Sandler reduced their price objective on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Avadel Pharmaceuticals in a report on Monday. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of Avadel Pharmaceuticals in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Avadel Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $12.00 price objective for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Avadel Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $19.88.

Avadel Pharmaceuticals Trading Up 1.2 %

NASDAQ:AVDL opened at $7.64 on Wednesday. The stock’s 50-day moving average is $8.77 and its 200-day moving average is $11.54. Avadel Pharmaceuticals has a 1-year low of $7.39 and a 1-year high of $19.09. The stock has a market cap of $736.21 million, a P/E ratio of -9.67 and a beta of 1.28.

Insider Transactions at Avadel Pharmaceuticals

In other Avadel Pharmaceuticals news, Director Linda Palczuk bought 3,000 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was acquired at an average price of $10.19 per share, with a total value of $30,570.00. Following the completion of the purchase, the director now directly owns 66,400 shares of the company’s stock, valued at approximately $676,616. This trade represents a 4.73 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Thomas S. Mchugh purchased 5,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was acquired at an average cost of $10.49 per share, for a total transaction of $52,450.00. Following the completion of the purchase, the chief financial officer now owns 85,500 shares of the company’s stock, valued at approximately $896,895. This trade represents a 6.21 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 55,579 shares of company stock valued at $526,363. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC acquired a new position in Avadel Pharmaceuticals during the 3rd quarter worth approximately $31,000. Advisors Asset Management Inc. raised its position in shares of Avadel Pharmaceuticals by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock worth $104,000 after purchasing an additional 2,846 shares during the period. Hsbc Holdings PLC bought a new position in shares of Avadel Pharmaceuticals in the 4th quarter worth $113,000. Kazazian Asset Management LLC acquired a new stake in Avadel Pharmaceuticals in the 4th quarter valued at $126,000. Finally, Aigen Investment Management LP bought a new stake in Avadel Pharmaceuticals during the 3rd quarter valued at $160,000. Institutional investors own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.